European interest in Wegovy expected to match US demand, says EVP at Novo Nordisk

According to Martin Holst Lange, executive vice president for development at Novo Nordisk, Wegovy is predicted to receive just as warm of a welcome outside the US as it did when it was launched there in June.

Photo: Novo Nordisk / PR

Expectations for the European launch of the weight loss drug Wegovy are sky-high after the pharmaceutical company announced on Thursday that the European Medicines Agency's expert committee, the CHMP, has given a positive opinion on the treatment.

Now, Novo Nordisk is anticipating that the drug, which is built on the GLP-1 analog semaglutide, will be welcomed to the market with open arms by Europe, similar to its June launch in the US, where the drug has been a great success, EVP for Development at Novo Nordisk Martin Holst Lange tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs